Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carboplatin and Nab-Paclitaxel in Advanced NSCLC
NCT02382406Phase 2Terminated
- Start
- Jun 2015
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 cohorts). Primary endpoints: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Recommended Phase II Dose up to 2 years, Disease Assessment for Progression-Free Survival up to 9 months and 1 more. Started Jun 2015; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02382406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02382406.